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PRESCRIPTION DRUG IMPORTATION: AN 
EXPANDED FDA PERSONAL USE 
EXEMPTION AND QUALIFIED REGULATORS 
FOR FOREIGN-PRODUCED 
PHARMACEUTICALS 
 
Elliott A. Foote∗ 
 
ABSTRACT 
 igh-priced prescription drugs have been a problem for U.S. 
consumers. The United States market economy coupled with 
patent protection for these products creates an incentive for 
pharmaceutical companies to charge as much as possible. Unable to 
afford these drugs, many people are reaching out to neighboring 
countries and abroad to seek lower-cost options. It has also created a 
market for online mail-order pharmaceuticals. Despite the need for 
these drugs, the Food and Drug Administration (“FDA”) continues to 
make importation illegal.  
In formulating its policy, the FDA cites to safety and 
innovation concerns. Claimed uncertainty about the source of foreign 
prescription drugs has led to ineffective federal policy in this area. To 
date, none of the major amendments to the Food, Drug, and Cosmetic 
Act have successfully provided a framework for securing foreign 
importation. Without proper federal guidance, various states, 
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including Maine, have implemented legislation to facilitate the 
importation of prescription drugs from other developed countries like 
Canada and England. 
This Article proposes two potential solutions to implement 
policy on the federal level. With an eye towards Maine’s new law and 
its successes, there is potential for an expanded, codified personal use 
exemption. Moreover, using “qualifying” countries, or those with an 
adequate level of manufacturing oversight for prescription drugs, may 
provide an alternative safeguard for allowing importation. 
I. INTRODUCTION 
U.S. citizens travel to other countries to obtain medical 
treatment and prescription drugs because of high local prices. 
Prescription drug costs in America are much higher than in other 
surrounding countries. Yet, importing these medications remains 
illegal. “Medical tourism” is the umbrella term used to describe going 
abroad to receive medical services or treatment. Tourism can include 
major surgical procedures, prescription drugs, or other medical 
treatments like dentistry.1 This practice has become a lucrative trade 
for the countries facilitating cheap healthcare and medications.2 
The people who are harmed most by criminalizing this 
conduct, however, are those who have terminal illnesses and serious 
conditions but remain unable to afford costly treatments. In 
desperation, some people resort to traveling across the border to 
nearby countries like Canada and Mexico3 to buy prescription drugs. 
                                                
1 See I. GLENN COHEN, PATIENTS WITH PASSPORTS: MEDICAL TOURISM, LAW, 
AND ETHICS (2015); see also JILL R. HODGES & ANNE MARIE KIMBALL, RISKS AND 
CHALLENGES IN MEDICAL TOURISM: UNDERSTANDING THE GLOBAL MARKET FOR 
HEALTH SERVICes (2012) (discussing the American incentive for crossing the 
border to obtain healthcare). 
2 Mexico Second in Medical Tourism, Government Reports, MEX. GULF REP. 
(Feb. 9, 2104), http://www.mexicogulfreporter.com/2014/02/mexico-second-in-
medical-tourism.html (noting medical tourism as a three billion dollar business for 
Mexico in 2013). 
3 Lorne Matalon, Desperate Patients Smuggle Prescription Drugs from Mexico, 
MARKETPLACE HEALTHCARE (Jan 20, 2014), 
http://www.marketplace.org/topics/health-care/desperate-patients-smuggle-
prescription-drugs-mexico; see also Michele L. Creech, Make a Run for the Border: 
Why the United States Government is Looking to International Market of Affordable 
Prescription Drugs, 15 EMORY INT’L L. REV. 593, 643 (2001); Helkei Tinsley, 
 
Foote Article.docx (Do Not Delete)  5/1/15  10:29 PM 
2015 Prescription Drug Importation 371 
More recently, large numbers of people and entities locally buy bulk 
foreign drugs online and have them shipped to the United States to 
meet their medical needs. Needless to say, both options have received 
harsh treatment by the United States government. Recognizing the 
government’s policy toward importation, others have pushed for 
price-caps on drugs, but to no avail.4 
With the proper policy push, however, America could be on 
the verge of a drug importation breakthrough. A new law on 
prescription drug importation in Maine may hold at least one of the 
keys to lower the high prices of prescription drugs throughout the 
United States—evidence of successful implementation and safety. 
The problem of high-priced prescription drugs is longstanding,5 and 
remains a concern due to a number of policy barriers preventing both 
efficient importation and price competition.  
In response, the U.S. government has attempted to 
incrementally adjust its stance to combat this increasingly difficult 
area of regulation, but has yet to implement a satisfactory framework. 
Such a framework, however, is possible with a close look at proposed 
legislation before Congress as well as the newly passed importation 
law in Maine. Moreover, Maine’s program suggests American 
citizens desire better importation policy while also hinting at the 
potential for success on the national level. 
This Article will discuss the issues surrounding the 
importation of prescription drugs into the United States and will 
propose solutions that build on existing policy through economic 
efficiency arguments and diverting regulatory efforts. Part I provides 
the background for the problem of high-price prescription drugs and 
the influence of illegality on consumer behavior. Part II will explain 
the modern state of prescription importation laws, the newly passed 
importation law in Maine, and the Food and Drug Administration’s 
concerns with importation. Part III proposes the use of an expanded, 
codified personal use exemption and an established regulation 
                                                
Prescription Without Borders: America Looks to Canada for Answers to Solve the 
Prescription Drug Pricing Predicament in the U.S., But is Importation Really the 
Solution?, 25 HAMLINE J. PUB. L & POL’Y 437, 438 (2004). 
4 See Jerry Stanton, Comment, Lesson for the United States from Foreign Price 
Controls on Pharmaceutical, 16 CONN. J. INT’L L. 149 (2000). 
5 See Gadler v. United States, 425 F. Supp. 244 (D. Minn. 1977). 
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program for foreign manufacturers to register with the FDA along 
with a permitted substance listing. 
II. THE ISSUES OF PRESCRIPTION DRUG IMPORTATION 
Facilitating access to useful prescription drugs in the United 
States faces two major problems. First, consumers of prescription 
drugs face prohibitively high prices in the United States, which often 
encourage them not to purchase necessary medications. The United 
States’ free market economy, patent protection, and the lack of an 
effective price board (e.g., an independent agency regulating 
pharmaceutical prices) entrenches these high prices. The problem 
becomes even more complicated when reviewing the heavily 
entrenched pharmaceutical industry interest in legislation and attempts 
to keep this industry highly profitable. Second, seeking out 
prescription drugs at lower prices from countries like Canada and 
Mexico is technically illegal and uncertain, and thus has a deterrent 
effect for risk-averse individuals.6 
A. High-Price Prescription Drugs 
As mentioned in the introduction to this Article, consumers in 
the United States tend to pay significantly more for prescription drugs 
than people in other countries. A simple comparison to United States 
price norms to Canada is illustrative of this issue—though other 
countries maintain comparably better-priced pharmaceuticals as well.7 
In 2004, the median prescription drug prices in Canada were as much 
as 78.6% lower than those in the United States.8 In 2006, Brian Beirne 
                                                
6 See Maine Enacts Law Enabling Prescription Drug Importation, CHAIN DRUG 
REV. (June 28, 2013), http://www.chaindrugreview.com/newsbreaks-archives/2013-
06-24/maine-enacts-law-enabling-prescription-drug-importation (“Americans have 
accessed medication internationally for over the past decade, but federal 
prohibitions on personal drug importation, while not enforced against individuals, 
have deterred millions.” (internal quotation marks omitted)). 
7 See Patricia M. Danzon & Michael F. Furukawa, Prices and Availability of 
Pharmaceuticals: Evidence from Nine Counties, HEALTH AFFAIRS (Oct. 29, 2003), 
available at 
http://content.healthaffairs.org/content/early/2003/10/29/hlthaff.w3.521.full.pdf+ht
ml. 
8 Logan Beirne & Michael Tucker, Reimportation of Canadian Prescription 
Drugs into the United States: Regulatory, Economic, and Policy Implications, 10 
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and Michael Tucker conducted a comparative study through several 
100-count medication prices and found over $1,000 in aggregate 
difference between the ten selected prescriptions.9 Per the 2013 
Annual Report of the Patented Medicine Prices Review Board—
Canada’s prescription drug price board—the average price ratio 
shows consumers in the United States paying over double for 
patented-drug products compared to Canadian consumers, a trend that 
will likely increase in the coming years.10 Even generic drugs, an 
oft-cited solution to high-priced prescription drugs, have shown price 
hikes by as much as 17.7% in the past year.11 
With such high prices, many consumers either cannot afford 
their medication or make the conscious decision to “go without.” A 
Consumer Reports survey returned that “28% of chronically ill adults 
taking regular medications for their conditions reported skipping 
doses or not filling their prescriptions because they could not afford to 
pay for it,” which is a 1% increase from the year before.12 This is 
particularly interesting given the inelastic demand for medical 
treatment in general. That prescription drug prices are so high as to 
deter filling prescriptions for chronic illnesses speaks volumes.  
Why, then, does the United States struggle with prescription 
drug costs? The obvious answer can be found in its economic system. 
                                                
MICH. ST. U. J. MED. & L. 491, 493–94 (2006) (citing Patent Medicine Prices 
Review Board Annual Report 24 (2004)). 
9 Id. at 520 exh. 1. 
10 See PATENT MEDICINE PRICE REVIEW BOARD ANNUAL REPORT 24 fig. 9 & 
25 (2013), http://www.pmprb-
cepmb.gc.ca/CMFiles/Publications/Annual%20Reports/2013/2013-Annual-
Report_2013-09-15_EN.pdf (noting a 107% average price differential and that even 
accounting for cost of living, the United States and Germany still have larger 
consumption costs). 
11 See, e.g., Ellen Jean Hirst, Generic Drug Prices Skyrocket in the Past Year 
(Nov. 21, 2014), http://www.chicagotribune.com/business/ct-rising-generic-drug-
prices-1102-biz-201411 
21-story.html; see also Susan Barry, Cost of Generic Drugs Soaring Due to 
Increased Demand From Obamacare (Feb. 1, 2014), http://www.breitbart.com/Big-
Government/2014/01/31/Why-Are-Costs-For-Generic-Medications-Soaring. 
12 Shari Roan, Americans Struggle to Pay for Prescription Drugs, TAKEPART 
(Sept. 12, 2012), http://www.takepart.com/article/2012/09/11/americans-struggling-
pay-prescription-drugs (noting survey through landline/cellphone “randomized 
nationally represented sample of 4,432 adult ages 19 and older living in the 
continental US”). 
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Unlike the rest of the world that uses price boards to control drug 
prices, the United States allows pharmaceutical companies to set the 
market price.13 A few major players dominate the market through 
patent control and market share, which creates a sort of oligopoly 
between the pharmaceutical companies.14 This also creates a strong 
incentive to price gouge consumers for high profit. To demonstrate 
the incentive, the sale of prescription drugs constitutes a $300 billion 
industry worldwide with profit margins as high as 30%.15 In the 
United States alone, prescription drug sales yield $329.2 billion in 
gross revenue.16 And due to the political clout of the pharmaceutical 
lobby,17 the federal government has shown little, if any, desire to 
adopt prescription price controls.18 Efforts to cap prices have been 
characterized as a “slowing innovation” and “rewarding special 
                                                
13 Beirne & Tucker, supra note 8, at 494 (noting “patent protection often limits 
substitute products creat[ing] highly inelastic demand not seen with other 
products.”). 
14 Top Pharma Companies by Global Sales, PMLIVE (last visited Nov. 27, 
2014), http://www.pmlive.com/top_pharma_list/global_revenues. 
15 Pharmaceutical Industry, WORLD HEALTH ORG. (last visited Nov. 27, 2014), 
http://www.who.int/trade/glossary/story073/en/ 
16 Spending on Medicines, IMSHEALTH (Apr. 15, 2014) 
http://www.imshealth.com/deployedfiles/ 
imshealth/Global/Content/Corporate/IMS%20Health%20Institute/Reports/US_Use_
of_Meds_2013/2013_Medicine_Spending.pdf (charting medication spending, 
including $329.2 billion the in US). 
17 Martin L. Hirsch, Side Effects of Corporate Greed: Pharmaceutical 
Companies Need a Dose of Corporate Social Responsibility, 9 MINN. J. L. SCI. & 
TECH. 607, 631 (2008) (citing Julian Borger, Industry that Stalks the U.S. Corridor 
of Power, GUARDIAN, Feb. 13, 2001) (noting that “[t]he pharmaceutical lobby is 
recognized as the most powerful lobby in Washington); see also Beirne & Tucker, 
supra note 8, at 493 (noting the pharmaceutical industry spent “$675 million on 
lobbying and employ[ed] more than three thousand lobbyists between July 1998 and 
July 2005”). 
18 Julie Appleby, Got Insurance? You Still May Pay a Steep Price for 
Prescriptions, ST. LOUIS POST-DISPATCH (Oct. 13, 2014, 10:48 AM), 
http://www.stltoday.com/news/special-reports/mohealth/got-insurance-you-still-
may-pay-a-steep-price-for/article_5fd08e32-725f-535e-a7a1-5776f403f91a.html 
(noting presence of state legislative response and “debate over how to slow the rapid 
rise of spending on prescription drugs,” but also that “more direct government 
influence on prices drug makers can charge . . . is still seen as a political 
nonstarter”). 
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interests.”19 As a result, consumers in the United States continue to 
pay more than other countries, while nearby Mexico and Canada 
enjoy attractive pricing for the same medications.20 
B. Illegality 
From these price concerns, some people are turning to places 
like Canada and Mexico to fill their prescriptions or ordering drugs 
online through Internet pharmacies. Efficient behavior dictates that 
people will often seek out substitute goods in different markets if the 
price is significantly lower, so long as quality remains comparable.21 
However, both activities—going across the border to bring drugs back 
and ordering them online from other countries—are illegal.22 Thus, as 
it stands, people must choose between paying exorbitant prices, 
risking prosecution from illegal importation, or going without their 
medication. Wrongful importation can result in criminal charges 
against the importer, depending on the amount imported, usually a 
federal misdemeanor resulting in a potential year in jail and/or fine of 
$1,000 per violation.23 Larger or subsequent violations are punished 
with anywhere from 3–10 years in jail, or $10,000 to $250,000 in 
fines, or both.24 The seizures, charges, and fines are even larger for 
bulk importation from Internet pharmacies and other outlets. 
Recently the FDA has even begun taking online pharmacies to 
task, shutting them down and seizing their assets to make an example 
                                                
19 Phil Kerpen, Price Controls for Prescription Drugs Would Reward Special 
Interests and Slow Innovation, DAILY CALLER (Oct. 27, 2014, 4:30 PM), 
http://dailycaller.com/2014/10/27/price-controls-for-prescription-drugs-would-
reward-special-interests-and-slow-innovation/. 
20 Danzon & Furukawa, supra note 7. 
21 Valentino Piana, Substitute Goods, ECON. WEB INST. (2005), 
http://www.economicswebinstitute.org/glossary/substitute.htm 
22 21 U.S.C. § 331(t) (prohibiting “importation of a drug in violation of section 
381(d)(1), regarding importation of un-approved foreign drugs”); see also § 381 
(addressing importation and reimportation of prescription drugs). 
23 21 U.S.C. § 333(a)(1); see also Edward Lamb, When is it OK to Import a 
Prescription Drug into the U.S. for Personal Use?, ABOUT.COM, 
http://pharmacy.about.com/od/Technology/f/When-Is-It-Ok-To-Import-A-
Prescription-Drug-Into-The-U-S-For-Personal-Use.htm (last visited Nov. 27, 2014). 
24 21 U.S.C. § 333(a)–(b) (2012). 
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against this type of conduct.25 The FDA has shut down several 
pharmacy operations for illegal importation in violation of its 
approval authority, including more well-known cases such as Rx 
Depot and “Canada Care Drugs, Inc.”26 It has also made efforts to 
shut down other businesses that facilitate the importation of these 
prescription drugs. For example, three years ago, Google was forced 
to forfeit $500 million in online advertising revenue for “assisting” 
Canadian and other foreign online pharmacies to sell prescription 
drugs.27 Despite attempts by the FDA to shut down these operations, 
however, numerous foreign pharmacies websites exist and function 
for United States citizens to buy prescription drugs online.28 
The problem with the FDA’s punitive function is it deters at 
least some people from seeking low-priced prescription drugs. 
Though the FDA may disagree—for reasons, including safety and 
innovation, discussed below—there is no real reason to continue 
preventing this type of drug importation for cheaper prescription 
drugs and efficient access. The basic push of this Article, then, is the 
need to develop some method to allow the efficient transfer of these 
foreign-manufactured drugs into the United States to allow a lower-
cost alternative to high-priced prescription-drug options. To explain 
the necessity for this change, it is first necessary to walk through the 
                                                
25 See Press Release, FDA, Permanent Court Order Halts Illegal Importation of 
Prescription Drugs (March 31, 2006), 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm10862
7 
.htm (recounting investigation and injunction of Canada Care Drugs Inc. 
operations).  
26 United States v. Rx Depot, Inc., 290 F. Supp. 2d 1238 (N.D. Okla. 2003) 
(upholding injunction); Press Release, FDA, Permanent Court Order Halts Illegal 
Importation of Prescription Drugs (Mar. 31, 2006), 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements 
/2006/ucm108627.htm. 
27 Press Release, Department of Justice, Google Forfeits $500 Million 
Generated By Online Ads & Prescription Drug Sales by Canadian Online 
Pharmacies (Aug. 24, 2011), http://www.justice.gov/ 
opa/pr/google-forfeits-500-million-generated-online-ads-prescription-drug-sales-
canadian-online (explaining that it is illegal to aid or facilitate importation and 
marketing of illegal prescription drugs to U.S. citizens). 
28 See, e.g., Canadian Generic Pharmaceutical Association, CGPA, 
http://www.canadiangenerics.ca/ 
en/index.asp (last visited Nov. 2, 2104). 
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current state of prescription drug law and its inadequacies at 
addressing these issues of access, price, and importation. 
III. CURRENT IMPORTATION LAW 
 This Part will address the current state of the law surrounding 
prescription drug importation in two major parts. First, it will discuss 
issues under the Federal Food, Drug, and Cosmetic Act (FFDCA), 
including major amendments and importation exceptions. Second, it 
will evaluate the concerns—safety and innovation—raised by the 
FDA in maintaining the prohibition on prescription drug importation. 
Third, it will discuss the various attempts at state regulation of 
prescription drug importation. Fourth, this Part will address Maine’s 
new prescription drug importation legislation as a laboratory for 
federal policy. These issues will be discussed in turn. 
A. Federal Food, Drug, and Cosmetic Act 
The FDA regulates all aspects of prescription drugs in the 
United States, including manufacturing, production, and transport. Its 
original authority comes from the Federal Food, Drug, and Cosmetic 
Act of 1938, which also allows it to regulate the import and export of 
prescription drugs.29 Under the Act, the FDA has the authority to 
establish procedures for the monitoring and approval of new drugs.30 
Its power extends to enforcement against violations of these regulated 
areas under the FFDCA as well.31 As discussed above, the FDA also 
leads investigations to seize wrongfully imported and counterfeit 
drugs.32 The United States Customs and Border Protection (CBP), 
with FDA guidance, helps to enforce prescription drug mandates 
                                                
29 21 U.S.C. § 381(d) (2012).  
30 21 C.F.R. pt. 314 (2014). 
31 See 21 C.F.R. § 1.4 (2001). 
32Imported Drugs Raise Safety Concerns, U.S. FOOD & DRUG ADMIN., 
http://www.fda.gov/ 
Drugs/ResourcesForYou/Consumers/ucm143561.htm (referencing a 2002 FDA 
investigation where agents uncovered “more than 25,000 counterfeit Viagra 
pills . . . [supplied] from China and India”) (last updated Aug. 24, 2011). 
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against importation.33 This includes a ban on “the importation of 
prescription drugs that were purchased outside the United States.”34 
All drugs imported into the United States require FDA 
approval.35 The FDA has this authority through the power to regulate 
drugs issued into “interstate commerce,” which also includes foreign 
importation.36 Additionally, drugs imported into the United States 
must conform to labeling and manufacturing requirements set by the 
FDA, which also happens to be among the strictest standards set by a 
regulating agency worldwide.37 Once inside the United States, 
approved prescription drugs are processed through a “closed” 
distribution system.38 As such, the only people able to receive the 
imports are U.S.-licensed pharmacists and wholesalers. 
1. Personal Use Exemption 
Due to difficulties regulating individual importation, in 1954 
the FDA issued a personal use exemption for individual people to 
import up to a ninety-day supply under certain conditions.39 The 
statute provides the FDA power to “exercise discretion to permit 
individuals to make such importations in circumstances in which the 
importation is clearly for personal use . . . [and] the prescription drug 
or device imported does not appear to present an unreasonable risk to 
the individual.”40 The personal use exemption, however, is a 
discretionary guidance on the FDA’s choice to allow importation 
rather than a legally binding exception that importers may rely upon.41 
                                                
33 Prohibited and Restricted Items, U.S. CUSTOMS & BORDER PROT., 
http://www.cbp.gov/travel/ 
international-visitors/kbyg/prohibited-and-restricted-items (last visited Nov. 2, 
2014). 
34 Id. 
35 Imported Drugs Raise Safety Concerns, supra note 32. 
36 Id. 
37 Id. (explaining FDA requirements and foreign-registered manufacturer 
inspections). 
38 Id. 
39 Id.; see also Prohibited and Restricted Items, supra note 33. 
40 21 U.S.C. § 384(j)(1)(B) (2003). 
41 See Imported Drugs Raise Safety Concerns, supra note 32; Peter S. Reichertz 
& Melinda S. Friend, Hiding Behind Agency Discretion: The Food and Drug 
Administration’s Personal Use Drug Importation Policy, 9 CORNELL J. L. & PUB. 
POL’Y 493 (2000). 
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There is no right to import prescription drugs for personal use. Thus, 
people looking to import prescription drugs for personal use lack 
certainty and guidance. 
In 1988, the FDA used the personal use exemption to save 
regulatory resources and allow importation of new AIDS drugs 
against an epidemic. It modified the personal use exemption for the 
benefit of drugs where no equivalent was available, or approved for 
use, in the United States.42 The personal use exemption currently 
includes the following factors for use in the FDA’s discretionary 
ruling whether to enforce: 
 
Ø if the intended use is for a serious condition without 
effective domestic treatment available; 
Ø if the product is considered to represent an unreasonable 
risk; 
Ø if the individual seeking to import affirms in writing that it 
is for personal or patient use and provides the name and 
address of the U.S.-licensed doctor responsible for the 
treatment; 
Ø if there is evidence that the drug is for continuation of a 
treatment begun in a foreign country; 
Ø if the product is for personal use and is a three-month 
supply or less and not for resale, since larger amounts 
suggest commercial use; and 
Ø if there is a known commercialization or promotion to U.S. 
residents by those involved in distribution of the product.43 
While this exemption would seem to provide a reasonable allowance 
for personal importation of necessary treatment, in reality it is a 
narrow application with difficult-to-satisfy criteria. Specifically, it is 
difficult to imagine a serious condition in modern times where the 
                                                
42 See Benten v. Kessler, 799 F. Supp. 281, 282 (E.D.N.Y. 1992) (criticizing the 
personal use exemption as an “ill-considered promulgation” in a case involving an 
FDA import alert banning importation of RU486, an experimental abortion drug); 
see also Imported Drugs Raise Safety Concerns, supra note 32. 
43 Marvin A. Blumberg, Information on Importation of Drugs, U.S. FOOD & 
DRUG ADMIN, http://www.fda.gov/ForIndustry/ImportProgram/ucm173751.htm 
(last updated June 30, 2010); See also Imported Drugs Raise Safety Concerns, supra 
note 32. 
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United States has no comparable “effective domestic treatment.”44 
Moreover, drugs purchased in a foreign country, even by the same 
name as a United States counterpart, are likely not FDA-approved and 
would not meet the importation standards under its regulation.45  
 The personal use exemption has largely been ineffective at 
either providing relief for importation or helping to regulate the flow 
of unapproved, and thus illegal, prescription drugs. Not only has the 
personal use exemption failed to provide a safe haven in legitimate 
cases, it has not discouraged attempts at technically illegal 
importation by people willing to risk violation and has not helped to 
decrease prices, nor increase access.46 On the other hand, it has 
discouraged many people who need medication from seeking it out at 
the risk of committing a crime.47 
2. Reimportation 
Another commonly posited solution to high-price prescription 
drugs in the United States is the practice of so-called drug 
“reimportation.” Drug reimportation is when American drug 
manufacturers export their products to foreign countries, adjust them 
to price norms in those countries, and designate them for sale there.48 
Once the product is abroad, price boards of nearly all other developed 
countries49 dictate a lower price for the exported drug. At this point, 
                                                
44 As a matter of history, the personal use exemption was most widely used to 
justify importation of early experimental Cancer medication and some abortion 
drugs. See, e.g., Benten, 799 F. Supp. at 281; see also Gadler, 425 F. Supp. at 244. 
45  See 21 U.S.C. § 331 (2013) (prohibiting interstate shipment of unapproved 
new drugs). 
46 Importation of Drugs into the United States: Hearing Before the Subcomm. 
on Oversight and Investigations of the H. Comm. on Energy and Commerce, 107th 
Cong. (2001) (statement of William K. Hubbard, Senior Associate Commissioner 
for Policy, Planning, and Legislation, Food and Drug Administration), available at 
http://www.fda.gov/NewsEvents/Testimony/ucm115214.htm (discussing personal 
importation and oversight issues in mail and over the border). 
47 See Maine Enacts Law Enabling Prescription Drug Importation, supra note 
6. 
48 See Imported Drugs Raise Safety Concerns, supra note 32; see also Monali J. 
Bhosle & Rajesh Balkrishnan, Drug Reimportation Practices in the United States, 
3(1) THERAPEUTICS & CLINICAL RISK MGMT. 41, 41–42 (2007). 
49 Paula Tironi, Pharmaceutical Pricing: A Review of Proposals to Improve 
Access and Affordability of Prescription Drugs, 19 ANNALS HEALTH L. 311, 352 
(2010). 
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individual consumers may solicit particular prescriptions from foreign 
pharmacies at a lower price and have them shipped back into the 
United States at a minimal cost that generates a net savings.50 This 
idea also presents a price discrimination issue, whereby some 
consumers willing to pay for higher-price drugs will buy them 
domestically, while others less willing will choose to go abroad for 
their medications.51 Further, perhaps the idea of needing to export 
products to a foreign market where the price is regulated and then 
shipping it back domestically to gain savings demonstrates the 
absurdity of the current price system as it exists. 
On the flip side, the manufacturer, in theory, could reimport 
them into the United States and pass along the savings to consumers 
locally with reduced prices.52 Such is the theory of the FDA to the 
extent that it accepts the idea of reimportation, but this has yet to 
become an accepted practice.53 There is also very little incentive for 
manufacturers to engage in reimportation themselves, as imports back 
into the country must still abide by the FDA’s costly regulations.54 On 
the other hand, pharmaceutical companies still benefit from having 
this extended market to tap into these consumers who are less willing 
to pay high prices domestically. 
Further complicating this problem, it is difficult to track the 
origin of these “reimported” drugs,55 which has resulted in the FDA 
not implementing any reimportation policy to date.56 Given regulatory 
resource concerns, the FDA has trouble ensuring that the prescriptions 
coming back through the mail were, in fact, manufactured in the 
United States. If not manufactured domestically, it is unlikely that the 
drugs will meet the FDA’s requirements, and are thus unacceptable 
                                                
50 Bhosle & Balkrishnan, supra note 48, at 41–42. 
51 See Beirne & Tucker, supra note 8, at 501 (discussing European prescription 
drug model and prohibited price discrimination between countries). 
52 Bhosle & Balkrishnan, supra note 48. 
53 See Imported Drugs Raise Safety Concerns, supra note 32; see also Beirne & 
Tucker, supra note 8, at 493 (noting that PMAA “does not explicitly prohibit 
importation from other countries that adhere to safety requirements”). The issue 
becomes that meeting such requirements is extremely complicated, and thus 
prohibitive. Without making it officially illegal, it makes the reimportation de facto 
illegal. 
54 See Imported Drugs Raise Safety Concerns, supra note 32. 
55 Bhosle & Balkrishnan, supra note 48, at 41–42. 
56 See Carmona, infra note 65 and accompanying text. 
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for importation or sale in the United States. Even where the 
manufacturing regulation appears to be on par with the United States’, 
the FDA denies access.57 Furthermore, the burden of meeting 
importation standards rests with the importer and is often impossible 
to meet, even for the original manufacturers.58 
Nonetheless, it would seem that such an option, helping to cut 
cost, would still be sufficient. Per FDA policy, however, prescription 
drug reimportation is still viewed with suspicion.59 The FFDCA also 
includes several labeling and approval provisions that make it 
extremely difficult to reimport.60 Some scholars, on the contrary, have 
argued that reimportation is a valid option to encourage cost 
competition and eventually encourage government-mandated price 
caps on prescription drugs.61 To date, however, the FDA has yet to 
implement a reimportation policy, despite several FFDCA 
amendments aimed at integrating access and subsidizing prescription 
drug prices, which will be discussed in the following section. 
3. Recent Amendments 
There have been a number of FFDCA amendments in response 
to this issue of high prices and prescription drug access, but none have 
been sufficient at addressing the problem as it stands today, either 
through inadequate alternative solutions or failed implementation. 
This subsection will discuss the three most pertinent amendments in 
turn: (1) the Medicine Equity and Drug Safety Act of 2000; (2) the 
Medicare Prescription Drug, Improvement and Modernization Act of 
2003; and (3) the Food and Drug Administration Safety and 
Innovation Act of 2012. 
                                                
57 See Imported Drugs Raise Safety Concerns, supra note 32. 
58 Id. Additionally, the FDA has recently proposed counterfeit-resistant 
technology and other special requirements to make it more difficult to import 
prescription drugs. Beirne & Tucker, supra note 8, at 505. 
59 See Imported Drugs Raise Safety Concerns, supra note 32; Beirne & Tucker, 
supra note 8, at 505 (explaining safety risks of reimportation). 
60 Beirne & Tucker, supra note 8, at 500.  
61 Id. at 519. But see Devin Taylor, Importing a Headache for Which There’s 
No Medicine: Why Drug Reimportation Should and Will Fail, 15 J.L. & POL’Y 
1421, 1468 (2007) (advocating that drug reimportation is too dangerous). 
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In 2000, Senator Jim Jeffords proposed the Medicine Equity 
and Drug Safety Act (MEDS) in Congress.62 The Act had the 
objective of achieving reimportation success but was never passed in 
Congress due to alleged safety concerns by the Secretary of Health.63 
The bill recognized that “the cost of prescription drugs for Americans 
continue to rise at an alarming rate” and that “many life-saving drugs 
are available in countries other than the United States at substantially 
lower prices.”64 As such, it provided authority for the Secretary of 
Health to create and implement regulatory frameworks regarding both 
importation and reimportation of prescription drugs from foreign 
countries, including Canada.65 
As a renewed effort to address the issues of importation and 
popular pressure against high prescription prices, in 2003, Congress 
passed the Medicare Prescription Drug, Improvement and 
Modernization Act (MMA).66 This amendment implemented Part D 
Medicare benefits and also permitted the limited importation of 
certain drugs from Canada, closely mirroring the factors of the 
personal use exemption.67 While this amendment provided authority 
to allow importation, once again the Secretary of Health and Human 
Services never used the discretion to initiate this program.68 Thus, it 
subsidized some useful prescriptions through its Part D benefit, but 
the MMA amendment was largely ineffective in addressing 
importation concerns and never really provided legal support for 
                                                
62 Medicine Equity and Drug Safety Act of 2000, S. 2520, 106th Cong. (2000), 
available at https://www.govtrack.us/congress/bills/106/s2520#overview. 
63 Id.; see also Prescription Drug Re-Importation Question and Answer Sheet, 
AARP, 
http://assets.aarp.org/www.aarp.org_/articles/international/ReimportationQA.pdf. 
64 S. 2520 § 2 (referred to the Committee on Health, Education, Labor, and 
Pensions). 
65 Id. § 3. 
66Report of the HHS Task Force on Drug Importation: Hearing Before the 
Committee on Health, Education, Labor, and Pensions, U.S. Senate (2005) 
[hereinafter Report HHS Task Force], available at 
http://www.hhs.gov/asl/testify/t050216b.html (statement of Richard H. Carmona, 
Surgeon General of the U.S. Public Health Service).   
67 Daniel L. Pollock, Blame Canada (And the Rest of the World): The Twenty-
Year War on Imported Prescription Drugs, 30 SETON HALL LEGIS. J. 331, 349–51 
(2006); see Beirne & Tucker, supra note 8, at 500 (explaining MMA inclusion of 
Canadian imports and similarities to the personal use exemption). 
68  Report HHS Task Force, supra note 66. 
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importation. Rather, the FDA continued to take a “strong stance” 
against importation of prescription drugs for safety reasons, which 
later led to other creative state alternatives to federal law.69 
The most recent amendment to the FFDCA, passed on July 9, 
2012, as the Food and Drug Administration Safety and Innovation Act 
(FDASIA), was likewise inadequate at addressing the issue of drug 
importation,70 although the amendment acknowledges that a 
significant portion of finished drugs and active ingredients come from 
overseas sources.71 As a part of its content, the amendment expands 
the FDA’s authority to protect and monitor the drug supply chain of 
approved prescription drug materials and manufacturer 
reimportations.72 While providing for safer supply chains for 
U.S.-produced pharmaceuticals, the amendment does little, if 
anything, to address importation or price controls.73 
B. FDA’s Concerns 
The Agency puts forward two major concerns when discussing 
its decision to continue prohibiting importation: (1) the inability to 
ensure the safety of imported substances, and (2) that cheaper 
imported drugs would undercut the incentive for pharmaceutical 
companies to invest in research and development. The following 
subsections will discuss these issues in turn. 
1. Safety 
FDA importation policy mentions safety as a major concern 
for prescription drug importation. The safety concern is that the FDA 
                                                
69 Jennifer Micheletto, The Illinois Prescription Drug Plan: Will it Last? An 
Analysis of the Current State of Health Care, Congressional Efforts to Lower 
Prescription Drug Costs, and Illinois’ Response to High Prices, 9 DEPAUL J. 
HEALTH CARE L. 1261, 1261 (2006).  
70 Food and Drug Administration Safety and Innovation Act (FDASIA), FOOD & 
DRUG ADMIN., 
http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosme
ticActFDCAct/SignificantAmendmentstotheFDCAct/FDASIA/ (last updated 
October 28, 2014). 
71 Id. (noting 40% of all finished drugs and 80% of the raw ingredients come 
from abroad). 
72 Id. 
73 Id. 
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cannot know where certain drugs originate and is unable, given its 
resources, to verify the content of all imports.74 While this problem 
certainly exists, especially for developing countries and indeterminate 
sources, it is significantly overstated as a barrier for effective 
importation. For unapproved as well as approved drugs, the FDA 
typically cites safety standards and dangerous counterfeiting as the 
reasons for denying access to importation.75 Safety concerns receive 
disproportionate media coverage, but are not as significant as the FDA 
suggests, especially for countries with comparable manufacturing and 
transport regulatory schemes. 
The FDA’s concern for drug safety consists of at least six 
factors listed on its website and in importation literature: (a) Quality 
Assurance Concerns, (b) Counterfeit Potential, (c) Presence of 
Untested Substances, (d) Risks of Unsupervised Use, (e) Labeling and 
Language Issues, and (f) Lack of Information.76 Interestingly enough, 
all of these standards basically say the same thing, namely that drugs 
are not “safe.” 
In determining how to best handle this issue of safety, the 
FDA has implemented a “risk-based” approach to importation.77 
Under this approach, the FDA chooses when to exercise its 
prosecutorial discretion depending on how much of a risk is posed by 
a given importation, which is often denoted by “import alerts” for 
                                                
74 FDA Operation Reveals Many Drugs Promoted as “Canadian” Products 
Really Originate From Other Countries, FOOD & DRUG ADMIN. (Dec. 16, 2005), 
available at http://www.fda.gov/NewsEvents/ 
Newsroom/PressAnnouncements/2005/ucm108534.htm (alleging “Canadian” drugs 
typically originate in other countries). 
75 See Imported Drugs Raise Safety Concerns, supra note 32 (citing retired 
Regulatory Affairs officer, Joseph McCallion, stating, “If you buy drugs that come 
from outside the U.S., the FDA doesn't know what you're getting, which means 
safety can't be assured” (internal quotation marks omitted)).  
76 Looks Can Be Deceiving, FOOD & DRUG ADMIN. (Apr. 3, 2012), available at 
http://www.fda.gov/Drugs/ResourcesForYou/ucm078900.htm. 
77 Import, Counterfeit, and Unapproved Drugs: Hearing before the Subcomm. 
on Oversight and Investigations H. Comm. on Energy and Commerce (2003) 
(statement of William K. Hubbard, Associate Commissioner for Policy and 
Planning), available at http://www.fda.gov/NewsEvents 
/Testimony/ucm161030.htm (noting the FDA has responded to the influx of 
importations by “employing a risk-based enforcement strategy to deploy our 
existing enforcement resources in the face of multiple priorities”). 
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particularly dangerous shipments.78 It is for this reason that the FDA’s 
enforcement objectives have largely targeted the businesses that 
facilitate the importation rather than the individuals seeking the 
medication.79 Thus, for practical purposes, importation only becomes 
subject to an enforcement action once it becomes “commercial” in 
nature, or large enough to register profit as a business.80 To reflect this 
reality, recently the FDA proposed regulation allowing authority to 
seize and destroy improperly imported prescription drugs valued at 
less than $2,500, with the purpose of “increasing the integrity of the 
drug supply chain.”81  
This approach has received heavy criticism because of its 
apparent support for industry profit margins rather than securing 
safety for consumers, or effective deterrence.82 The same critics have 
also noted that the FDA often fails to test the drugs it seizes in busting 
up these operations—suggesting less than a true concern for safety by 
the FDA.83 It is also worth noting that enforcement that takes this 
approach removes one of the best consumer safeguards to consumer 
purchasing—the vendor. Entities, like online pharmacies and 
wholesalers, are often in a better position to negotiate precautions and 
safeguards for consumers.84  
Instead, the enforcement policy encourages behavior such that 
individuals, navigating the vast sea of prescription drugs online, are 
the ones bearing the safety risk, although perhaps not the legal one, of 
the imported drug because the FDA refuses to recognize legitimate 
sellers in this arena.85 Prosecuting vendors functions to discourage 
legitimate companies from selling to U.S. consumers, while leaving 
                                                
78 Id. 
79 JODY FEDER, CONG. RESEARCH SERV., RL 32191, PRESCRIPTION DRUG 
IMPORTATION AND INTERNET SALES: A LEGAL OVERVIEW, CRS 12-13 (2004). 
80 See id. 
81 See Administrative Destruction of Certain Drugs Refused Admission to the 
United States, 79 Fed. Reg. 25758 (Proposed May 6, 2014) (to be codified at 21 
C.F.R. pt. 1), available at https://www.federalregister.gov/articles/2014/05/06/2014-
10304/administrative-destruction-of-certain-drugs-refused-admission-to-the-united-
states; see also 21 U.S.C. § 381(b) (explaining disposition of refused articles). 
82 See id. 
83 FEDER, supra note 79.  
84 Bruce Watson, Need Cheap Medication? Move to Maine, DAILYFINANCE 
(Oct. 13, 2013), http://www.dailyfinance.com/on/cheap-medication-maine-
canadian-prescription-drugs/. 
85 See id. 
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the illegitimate vendors who will risk the sale regardless. Yet, despite 
FDA warnings about safety and uncertainty for imported drugs, some 
consumers are still purchasing these products from abroad.86 Even 
still, as a practical matter, the FDA policy turns a blind eye to the 
reality of most personal use importations,87 which begs the question: 
if knowing prohibition does not work and the FDA is concerned about 
safety, then why not regulate actively, instead of maintaining this 
umbrella prohibition?  
To continue discouraging the leap to a more liberal 
importation standard, the FDA periodically releases a story about the 
safety concerns and unpredictability of imported drugs.88 Likewise, it 
also attempts to debunk the “myth” that Canadian prescription drugs 
are somehow cheaper.89 While, at the same time, pharmaceutical 
companies continue to import their raw materials from foreign 
countries and even manufacture abroad.90 In one instance, the FDA 
                                                
86 FDA Finds Consumers Continue to Buy Potentially Risky Drugs Over the 
Internet: Practice Puts Consumer at Risk and May be More Expensive than 
Domestic Purchasing, FOOD & DRUG ADMIN. (July 2, 2007), 
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm10894
6.htm; see also FDA Test of Prescription Drugs from Bogus Canadian Website 
Show All Products are Fake and Substandard, FOOD & DRUG ADMIN. (July 13, 
2004), http://www.fda.gov/NewsEvents/Newsroom/ 
PressAnnouncements/2004/ucm108320.htm (explaining continued importation by 
United States citizens despite FDA warnings about safety). 
87 Neil Osterweil, The Letter (and Spirit) of Drug Import Law, WEBMD, 
http://www.webmd.com/ 
healthy-aging/features/letter-and-spirit-of-drug-import-laws (last visited Nov. 2, 
2014). 
88 Aaron Carroll, How Safe are your prescription drugs, CNN OPINION (Feb. 
24, 2014), http://www.cnn.com/2014/02/25/opinion/carroll-drugs-imported-safety/; 
see also FDA Test Results of Prescription Drugs from Bogus Canadian Website 
Show All Products Are Fake and Substandard, FOOD & DRUG ADMIN. (July 13, 
2004), http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ 
2004/ucm108320.htm (identifying Canadian drugs as fakes). 
89 See Linda Bren, Study: U.S. Generics Cost Less than Canadian Drugs, FOOD 
& DRUG ADMIN. (July, 2004), 
http://www.fda.gov/Drugs/ResourcesForYou/ucm134441.htm. 
90 See e.g., Jennifer L. Halser, Canadian Pharmacies: A Prescription for a 
Public Health Disaster, 54 DEPAUL L. REV. 543 (2005); Regulatory Information, 
Food and Drug Administration Safety and Innovation Act, FOOD & DRUG ADMIN., 
http://www.fda.gov/RegulatoryInformation/Legislation/ 
FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/F
DASIA/ (last updated Aug. 28, 2014) (noting “40 percent of finished drugs being 
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issued a press release detailing a 2003 drug seizure. It found that 88% 
of packaged drugs in the inspected shipment did not meet FDA 
standards.91 In another instance, the FDA seized packets in 2005 and 
found that 88% of the drugs, alleged from Canada, were produced in 
27 other countries.92 The National Association of Boards of Pharmacy 
(NABP), a professional association of pharmacists, has also been 
implicated in these attacks through sponsoring studies about the safety 
of Canadian online pharmacies.93 
Studies show, however, that the risks of counterfeiting and 
safety are probably much higher in developing countries than others 
with regulation similar to the United States. It is estimated that about 
30% of all drugs in developing countries are counterfeit,94 while only 
an estimated 1% of all drugs face this problem when exported from a 
developed country.95 Thus, importing from a developing, rather than 
developed, country has a significantly higher risk of being counterfeit. 
                                                
imported, and nearly 80 percent of active ingredients coming from overseas 
sources.”). 
91 Gilbert Ross, Why Drug ‘Reimportation’ Won’t Die, WALL ST. J. (Jan. 7, 
2010), 
http://online.wsj.com/articles/SB10001424052748704842604574642184130409874
. 
92 See FDA Operation Reveals Many Drugs Promoted as “Canadian” Products 
Really Originate From Other Countries, supra note 74. 
93 Save Money by Ordering Drugs from Canada? Not so Fast, CONSUMER REP. 
NEWS (Oct. 27, 2011 06:08 AM), 
http://www.consumerreports.org/cro/news/2011/10/save-money-by-ordering-drugs-
from-canada-not-so-fast/index.htm (attacking Canadian prescription drugs). The 
study reviewed 8,300 online pharmacies and found that around 3 % were actually 
“legitimate” operations. Id. Furthermore, 85% did not require a valid prescription 
from the customers, 44% offered foreign drugs or FDA-unapproved drugs, and 25% 
had physical addresses outside of the United States. Id. 
94 Judy Stone, Counterfeit Drugs: A Deadly Problem, SCI. AM. BLOG (Aug. 20, 
2012), http://blogs.scientificamerican.com/molecules-to-
medicine/2012/08/20/counterfeit-drugs-a-deadly-problem/; see also Priya Shetty, 
Counterfeit Drugs: Facts & Figures, SCIDEV.NET (Mar. 30, 2011), 
http://www.scidev.net/global/health/feature/counterfeit-drugs-facts-figures-1.html. 
95 Medicines: Spurious/Falsely-Labelled/Falsified/Counterfeit (SFFC) 
Medicines, WORLD HEALTH ORG. (May 2012), 
http://www.who.int/mediacentre/factsheets/fs275/en/ (noting that “incidences of 
SFFC medicines is extremely low” in Australia, Canada, Japan, New Zealand, the 
United States, and the European Union); see also Counterfeit Medicines, WORLD 
HEALTH ORG. (Nov. 14, 2006), 
http://www.who.int/medicines/services/counterfeit/impact/ImpactF_S/en/. 
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At 1% counterfeiting for developed countries, however, the risk seems 
fairly minimal in reality. 
The FDA argues that these safety concerns expand to all 
foreign countries, but evidence suggests that there is no such concern. 
In fact, some argue that safety concerns regarding countries like 
Canada are “unwarranted” and that safety standards in these countries 
are “very similar” to those required in the United States.96 For 
example, manufacturers in Canada must also comply with the “Good 
Manufacturing Practices” promulgated by the FDA,97 the 
quintessential quality standard requirement imposed on drug 
manufacturers.98 Several agencies, including the North American 
Pharmacy Accreditation Commission and Health Canada’s 
Therapeutic Product Directorate, regulate compliance and quality 
assurance.99 The process for approval also includes licensing of 
individuals engaged in the production and oversight of prescription 
drug manufacturing.100 Research also suggests that in Canada the 
“incident reporting of internal process errors [is] more rigorous […] 
than in the US,” which suggests a stronger feedback loop to minimize 
faulty drugs making it to the consuming public.101 
Similar to Canada, many European countries, among others, 
also utilize similar approval and quality assurance processes for 
prescription drugs.102 While some aspects of the process might differ, 
                                                
96 Beirne & Tucker, supra note 8, at 503–04 (“United States and Canada have 
comparable requirements at virtually every step in the process. Both nations require 
that quality control units test both the raw materials prior to production and the 
finished product.”); see also Petra Brhlikova, Ian Harper & Allyson Pollock, Good 
Manufacturing Practice in the Pharmaceutical Industry, CTR. FOR INT’L PUB. 
HEALTH POLICY (July 2–3, 2007), 
http://www.csas.ed.ac.uk/__data/assets/pdf_file/0011/38828/ 
GMPinPharmaIndustry.pdf.  
97 Id. at 504. 
98 Facts About Current Good Manufacturing Practices (cGMPs), FOOD & 
DRUG ADMIN., 
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Manufacturing/ucm16910
5.htm (last updated Oct. 23, 2014). 
99 Beirne & Tucker, supra note 8, at 504. 
100 Id. 
101 Id. 
102 See Medicines, MED. PRODUCTS AGENCY (Feb. 5, 2006), 
http://www.lakemedelsverket.se/ 
english/overview/About-MPA/Activities/Medicines/ (outlining Sweden’s regulatory 
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studies suggest that the European Union still achieves comparable 
safety levels while avoiding the delays of the FDA’s process.103 The 
FDA has even recognized the utility of sharing approval methods and 
process discussions with European and Scandinavian countries like 
Sweden.104 
2. Innovation 
The other argument that the FDA uses to justify prohibiting 
importation is a concern for stifled innovation. Some scholars argue 
that importation would be the first step in effective price controls for 
pharmaceuticals,105 while others feel that it would kill the incentive 
for investments in developing new, cutting-edge prescription drugs.106 
The basic argument is that allowing “backdoor price controls”—
through cheap imported drugs—will have this same effect.107 
Allowing importation will kill demand in the high-price market for 
pharmaceuticals, drastically cutting profits, which in turn will be 
siphoned from R&D operations.  
Despite this concern, it seems that there will always be 
consumers willing to pay high prices for brand-name goods.108 
Moreover, the federal government is often responsible for funding the 
majority of the most important pharmaceutical research for public 
                                                
agency process for approving new medicines and quality control measures used to 
maintain safety); see also Pharmaceutical Administration and Regulations in Japan, 
JAPAN PHARM. MFG. ASS’N 24 (2010), http://apps.who.int/ 
medicinedocs/documents/s18577en/s18577en.pdf (requiring adherence to the Good 
Manufacturing Practice for quality control of Japanese manufactured prescription 
drugs). 
103 See Ines M. Vilas-Boas & C. Patrick Tharp, The Drug Approval Process in 
the U.S., Europe, and Japan, 3 J. MANAGED CARE PHARMACY 459 (1997), 
http://amcp.org/WorkArea/Download 
Asset.aspx?id=5884. 
104 FDA – Swedish National Board of Health, FOOD & DRUG ADMIN. (Mar. 5, 
2009), 
http://www.fda.gov/InternationalPrograms/Agreements/MemorandaofUnderstandin
g/ucm107628.htm. 
105 See Beirne & Tucker, supra note 8, at 493. 
106 Ross, supra note 91. 
107 Id.; see also Kerpen, supra note 19. 
108 This issue links into the inelastic demand for prescription drugs and the 
demand for luxury goods in the United States in times of higher income. 
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health.109 Studies have found that between 1965 and 1992, as much as 
66% of the funding for important drugs was publicly-provided.110 
Thus private R&D is not the only, and certainly not the most 
significant, source of funding to develop important pharmaceuticals. 
All things being equal, maintaining public funding is perhaps more 
important than concerns about private incentives to develop. 
Moreover, pharmaceutical companies also receive such high profits—
at around 30%111—that cutting some profits will likely not 
significantly affect R&D.112 
C. State Importation Legislation 
In the early 2000s, given the lack of viable alternatives for 
cheap medicine, states began to implement their own laws to allow for 
the importation of prescription drug from certain countries including 
Canada.113 State intervention programs existed on a spectrum: some 
involved as little as informing consumers about the option for 
Canadian or foreign prescription drugs,114 while others implemented 
contractual plans with foreign pharmacies and wholesalers to facilitate 
the purchase of prescription drugs.115 In particular, the Illinois “I-
SaveRx” plan established “benefit-manager” relationships to purchase 
pharmaceuticals through countries like Canada, Ireland, and the 
United Kingdom.116 This more involved type of state intervention still 
only utilized personal use importation rather than facilitating state 
importation of FDA-restricted prescription drugs.117  
Not surprisingly, the FDA and pharmaceutical syndicates 
responded negatively to both types of programs regardless of the 
                                                
109 Beirne & Tucker, supra note 8, at 514. 
110 Id. at 514. 
111 Pharmaceutical Industry, supra note 15. 
112 See Beirne & Tucker, supra note 8, at 515. 
113 Micheletto, supra note 69, at 1261; Lynn Sweet, Illinois Defying Feds, 
Importing Rx Drugs; But FDA is Threatening to Take State To Court, CHI. SUN-
TIMES, Aug. 17, 2004, at 8. 
114 Micheletto, supra note 69, at 1277–78 (discussing Minnesota plan to inform 
consumers about “state-approved Canadian pharmacies” but not being “directly 
involved in importing prescription drugs” (internal quotation marks omitted)). 
115 Id. at 1279.  
116 Id. (citing Anna Wilde Mathews, Illinois to Set Up a Program to Promote 
Drug Importation, WALL ST. J., Aug. 17, 2004, at D4). 
117 Id. at 1279–80. 
Foote Article.docx (Do Not Delete) 5/1/15  10:29 PM 
392 Loyola Consumer Law Review Vol. 27:3 
degree of state involvement.118 It is difficult to ignore the benefit 
derived by these state programs in passing on savings to its citizens.119 
Despite the relative savings provided by these programs, the states 
that explored this type of legislation largely abandoned them in 2006 
when the prescription-drug benefit was added to Medicare via the 
MMA amendment implementation,120 as well as other programs 
expressly denied by the FDA.121 Others states, deterred by fears of 
violating federal law and risking infringement on FDA jurisdiction,122 
never implemented their own program, but nonetheless recognized the 
problem of high-price prescription drugs. Yet, even today, states 
continue attempting to contravene FDA policy and formulate 
importation programs,123 which shows the continued interest for 
import policy reform. 
D. Maine’s New Legislation 
The most recent state program to emerge is Maine’s “Act to 
Facilitate the Personal Importation of Prescription Drugs from 
                                                
118 Id. at 1278–80. 
119 See, e.g., Serena Lipski, Excessive Pricing and Pharmaceuticals: Why the 
Federal Patent Act Does Not Preempt State Regulation of Pharmaceutical Prices, 
39 U. TOL. L. REV. 913, 916–17 (2008); Micheletto, supra note 69, at 1261 (noting 
that Illinois state important law had “hopes of saving its citizens a significant sum of 
money”). 
120 See Kristin E. Schleiter, Court Support for FDA Regulation of Drug 
Importation, 11 AMER. MED. ASSOC. J. OF ETHICS 521 (2009); see also Jennifer 
Levitz & Timothy W. Martin, Maine to Allow Prescription-Drug Imports, WALL 
ST. J. (last updated Oct. 11, 2013), http://online.wsj.com/articles/ 
SB10001424052702303442004579123613325473946; Medicine Equity and Drug 
Safety Act of 2000, supra note 66. 
121 Vermont v. Leavitt, 405 F. Supp. 2d 466 (D. Vt. 2005); see also Schleiter, 
supra note 120. 
122 Ark. Att’y Gen. Op. No. 2001-035 (Mar. 15, 2001); Tenn. Att’y Gen. Op. 
No. 06-019 (Jan. 27, 2006); Tenn. Att’y Gen. Op. No. 05-083 (May 16, 2005) 
(deferring to FDA regulation and federal preemption); Tex. Att’y Gen. Op. No. GA-
0384 (Dec. 21, 2005). 
123 Jackie Farwell, British Pharmacy Chain Launches Online Drugstore for 
Maine Consumers, BANGOR DAILY NEWS (Nov. 27, 2014), 
http://bangordailynews.com/2014/10/07/health/british-pharmacy-chain-launches-
online-drugstore-for-maine-consumers/. 
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International Mail Order Prescription Pharmacies.”124 Under the law, 
Maine residents may import prescription drugs from licensed 
pharmacies in Australia, Canada, New Zealand, and the United 
Kingdom.125 The Maine Pharmacy Association, along with 
representatives of the pharmaceutical industry, recently filed suit 
challenging the law on various grounds.126 While the claims by 
pharmaceutical interests were dropped for lack of standing, the suit 
remains ongoing.127 
In discussing the Maine law, those in opposition use the same 
safety rhetoric used against the federal level policy.128 And as some 
suggest, perhaps it is more of a “turf” issue surrounding 
pharmaceutical profits rather than safety.129 Moreover, the benefits 
recognized by the program are quantifiable. Maine has consistently 
pushed the envelope in this arena since the first state programs back in 
the early 2000s.130 Between the years of 2004–2012, Maine residents 
experienced $3.2 million aggregate savings on prescription drugs.131 
Given that states have historically acted as the laboratories for federal 
policy,132 Maine’s success is a useful indicator for further individual 
                                                
124 S.P. 60, L.D. 171 126th Leg., 1st Reg. Sess. (Me. 2013), 
http://www.mainelegislature.org/ 
legis/bills/getPDF.asp?paper=SP0060&item=2&snum=126. 
125 See Maine Enacts Law Enabling Prescription Drug Importation, supra note 
6. 
126 Complaint, Maine Pharmacy Ass’n v. Mills, No. 1:13-cv-00347-NT (D. Me. 
2013), http://freepdfhosting.com/7c2bcf9ba9.pdf; Kurt R. Karst, Mainers and FDC 
Act Preemption “In,” and PhRMA and Foreign Commerce Clause “Out” in 
Dispute Over Drug Importation Law, FDA L. BLOG (May 20, 2014), 
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2014/05/page/2/. 
127 Ed Silverman, In Maine, the British are Coming…to Sell Prescription 
Medicines Online, WALL ST. J. (Oct. 8, 2014), 
http://blogs.wsj.com/pharmalot/2014/10/08/in-maine-the-british-are-coming-to-sell-
prescription-medicines-online/. 
128 Dave Sterrett, Maine Drug Reimportation law May Benefit Consumers if 
Safety Can Be Assured, CITIZENVOX (Oct. 24, 2014), 
http://www.citizenvox.org/2013/10/24/maine-drug-reimportation-law-may-benefit-
consumers/. 
129 Id. 
130 Id. 
131 Id. 
132 New State Ice Co. v. Liebmann, 285 U.S. 262, 386–87 (1932) (“To stay 
experimentation in things social and economic is a grave responsibility. Denial of 
the right to experiment may be fraught with serious consequences to the nation. It is 
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state policy reform. Not to mention, a fifty-state system of 
prescription drug import regulation would prove an administrative 
nightmare. A single regulator concerned with safety is important, but 
the FDA needs to relax its limits. 
IV. NORMATIVE SOLUTION 
A solution to the limited access and high price of prescription 
drugs is complicated, but attainable. Potential solutions to this issue 
could include everything from skipping FDA-approval rounds for 
desired importations, implementing price control boards, or closing 
patent loopholes to open up generic markets faster. None of these 
solutions, however, have garnered sufficient popular or governmental 
support to be a realistic possibility. A uniform federal policy allowing 
importation, on the other hand, would provide for efficient regulation 
and unprecedented access to already available prescription drugs. 
Rather than directly controlling prices through a board, allowing 
competition through imports could indirectly drive down price by 
putting pressure on U.S. pharmaceutical companies. With lower prices 
and increased access, there could be an efficient allocation of 
prescription drugs to U.S. citizens needing treatment.133  
At this time, the FDA is too cautious and makes it too difficult 
for people to get the medicines they want or need. FDA deterrence 
effectively functions as a large transaction cost to importing drugs and 
discourages an efficient market and maximum benefit to consumers. 
As mentioned in Part II.B, the FDA’s concern for safety is likely 
overstated and can largely be ameliorated by limiting accepted drug 
importation to other developed countries with a similar regulatory 
standard as the United States.134 Moreover, the government allowing 
                                                
one of the happy incidents of the federal system that a single courageous state may, 
if its citizens choose, serve as a laboratory; and try novel social and economic 
experiments without risk to the rest of the country. . . . If we would guide by the 
light of reason, we must let our minds be bold.”). 
133 With a lowered price and increased demand, might this create a shortage? 
While this is possible, especially for countries like Canada where the United States 
could bleed the supply, it would likely adjust in time. If more markets open their 
supply, potential shortage could be negated. 
134 See Part II.B, supra note 95–103. 
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importation of cheaper drugs would not significantly harm incentives 
for pharmaceutical innovation.135  
As such, the solution to pricing and access can be solved, on a 
federal level, in one of two ways that this Article proposes: (1) an 
expanded, codified personal use exemption, and (2) permitted 
importation of prescription drugs from similarly regulated foreign 
countries. Both of these proposals could include provisions writing 
out patent infringement in cases where the drug would otherwise be 
properly sold abroad.136 Moreover, legislation could list certain 
essential, non-addictive pharmaceuticals—like heartburn treatment, 
blood thinners, or cholesterol medicine—that may be deemed not to 
pose a “significant health risk.” This may also exclude highly 
scheduled controlled substances and other narcotics that are often 
subject to abuse. 
Recent bills have been submitted to Congress in continued 
attempts to resolve this importation issue. While none have received 
majority support for enactment, the bills include some interesting 
proposals that deserve a closer look.137 The Pharmaceutical Market 
Access and Drug Safety Act of 2011 (PMADSA) proposes the 
designation of qualifying countries and drugs to be allowed for 
importation.138 It also, like my proposals, would limit patent 
infringement where drugs would have been properly sold abroad and 
would establish a regulatory framework for Internet vendors.139 
Likewise, the Personal Drug Importation Fairness Act of 2013 
(PDIFA) proposes an extension of the personal use exemption based 
                                                
135 See Part II.B.2, supra note 106–111. 
136 See Pharmaceutical Market Access and Drug Safety Act of 2011, S. 319, 
112th Cong. (2011), 
https://www.govtrack.us/congress/bills/112/s319#summary/libraryofcongress 
(denoting exception for when “resale in the United States of prescription drugs that 
were properly sold abroad” as not constituting patent infringement). Recognizing 
the patent implications of an import proposal, and while this issue is pressing, it is 
outside of the scope of this article. For a discussion of state regulators and patent 
infringement issues, see Lipski, supra note 119. 
137 S. 319; see also Personal Drug Importation Fairness Act of 2013, H.R. 3715, 
113th Cong. (2013), available at https://www.congress.gov/bill/113th-
congress/house-bill/3715 (listing proposed factors to permit importation of foreign 
prescription drugs, including the “same active-ingredients” as an FDA approved 
counterpart and coming from a “qualified country”). 
138 S. 319. 
139 S. 319. 
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on similar active ingredients, strength, direct shipping, and origin 
from a “qualified” country.140 With these suggestions in mind, it is 
possible to see successful importation policy in action. 
A. Expanded Personal Use Exemption 
An expanded personal use exemption would remedy the 
uncertainty inherent in the current model.141 As it currently stands, 
personal use importers cannot be sure that their conduct will go 
unpunished, and the FDA discretionary standards do not establish a 
realistic chance for use of the exemption. Much like Maine’s 
legislation, a reliable importation right under federal law would 
provide an effective means to import drugs for personal use and 
would lead to savings for United States consumers.142 Similar to the 
PDIFA, it would also be important to allow the exemption to function 
in more instances. This could include an exemption past having “no 
domestic alternatives” as under the current framework, as well as a 
codification that would provide importer reliance.143 To the extent that 
an individual bearing their own cost for importation safety is 
problematic, there may also be potential for the legislation to include 
some method for the registration of international sellers and 
pharmacists as well.144 
B. Foreign Regulatory Quality 
Another potential effective method for providing cheaper 
prices and higher access to prescription drugs would be to permit 
drugs from foreign countries with regulatory methods similar to the 
United States. As described in Part II.B.1, the FDA is incorrect in its 
assumption that it is the only agency capable of ensuring safety for 
consumers. Rather countries with a similar quality control for drug 
manufacturing and oversight (e.g., a sufficiently acceptable regulatory 
body overseeing operations) should be included for potential 
                                                
140 H.R. 3715. 
141 Reichertz & Friend, supra note 41, at 493. 
142 Sterrett, supra note 128. 
143 See supra note 44 and accompanying text. 
144 S.P. 60, L.D. 171 126th Leg., 1st Reg. Sess. (Me. 2013). 
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importation of these goods.145 How far the geographical limitations 
should extend (e.g., which countries meet the level of being 
“qualified”)146 is unclear. What is clear, though, is the need for an 
expansion of this rule to allow for efficient pricing and access to 
useful medications. Moreover, Maine’s success with a similar 
expansion to Canadian and European pharmacies suggests a reliable 
policy that would be conceivable without risking major safety 
concerns. Such a policy may also include a list of acceptable 
pharmaceuticals or qualifying substances through matching active 
ingredients.147 
Two questions arise, however, with regard to this type of 
solution: (1) would this be a personal use or bulk importation basis? 
(2) might it include foreign importation or, alternatively, only 
domestic reimportation? On the first issue of importation amount, the 
legislation in Maine, on the one hand, only permits such importation 
from certain countries for “personal use.”148 I would argue, however, 
that suitable regulatory oversight and funneling of these medications 
through the proper channels in cooperating countries should negate 
concerns for importing larger amounts of these medications from 
foreign countries. Similarly, with regard to importing foreign drugs 
versus reimporting domestically produced drugs, proper foreign 
oversight could potentially disavow the need to limit policy to merely 
a reimportation of domestically manufactured prescription drugs.149 
V. CONCLUSION 
In conclusion, this Article proposes two potential, 
nonexclusive solutions to progress prescription drug importation 
policy in the United States and bridge the regulation gap that currently 
exists today. These solutions could set up an efficient, cost-effective 
                                                
145 Id.; see also H.R. 3715. 
146 See e.g., H.R. 3715 (designating “qualified” countries generally without 
providing specific guidelines for designation). But see supra note 95 (denoting 
countries with “extremely low” instances of counterfeit or misleading medication at 
1%). Perhaps these same countries could serve as a baseline for opening 
importation. 
147 H.R. 3715 (listing use of the “same active ingredient” as one factor in 
permissible drug importation). 
148 S.P. 60. 
149 See infra note 94 and accompanying text. 
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market for prescription drugs, while simultaneously solving the 
problem of access to medications due to price. It seems important, if 
not necessary, in our increasingly globalized world to expand this 
commercial interchange between countries. Even larger—yet 
immeasurable—potential benefits past monetary savings may later 
manifest as well, such as increased access to effective medication 
affecting overall healthcare or commercial interchange bringing up 
prescription drug quality standards in more countries worldwide. 
 
 
